Recent Updates
Recently added Catalysts
QNRX Positive Sentiment Score: 65/100

Quoin Pharmaceuticals Announces Second Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday August 3rd at 8:30 am ET

Thursday, July 27, 2023 2 min read
Key Takeaway: Quoin Pharmaceuticals Ltd. will release its second quarter 2023 financial results on August 2, 2023, followed by a conference call scheduled for August 3, 2023. The call aims to discuss the financial results and provide a corporate update. Quoin focuses on developing therapies for rare diseases and has four products in its pipeline, emphasizing its commitment to addressing unmet medical needs.

Market Sentiment Analysis

POSITIVE FACTORS

  • Quoin Pharmaceuticals is releasing its second quarter financial results, indicating ongoing corporate activity.
  • The company is focused on addressing unmet medical needs for rare and orphan diseases, showcasing its commitment to innovation.
  • Quoin has a pipeline with four products in development targeting various rare diseases, suggesting potential growth.

Full Press Release Details

ASHBURN, Va., July 27, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its second quarter 2023 financial results after the market closes on Wednesday, August 2, 2023.
The Company will host a conference call and webcast at 8:30am ET on Thursday, August 3, 2023. The call will include a discussion of second quarter 2023 financial results and a corporate update.
The live call can be accessed by dialing 1-800-603-0527 (domestic) or 1-412-317-0688 (international).
The live and archived webcast of the call will also be available on the Quoin Pharmaceuticals website under the Investors section or by following this link:
https://event.choruscall.com/mediaframe/webcast.html?webcastid=muuHtkcD
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.
For further information, contact:
sprince@pcgadvisory.com

Frequently Asked Questions

When will Quoin Pharmaceuticals release its Q2 2023 financial results?

Quoin Pharmaceuticals will release its Q2 2023 financial results after market close on August 2, 2023.

What time is the conference call scheduled for?

The conference call is set for 8:30am ET on August 3, 2023.

How can I access the live call?

You can join the live call by dialing 1-800-603-0527 or 1-412-317-0688.

What diseases does Quoin Pharmaceuticals focus on?

Quoin Pharmaceuticals targets rare and orphan diseases with its therapeutic products.

Where can I find more information about Quoin Pharmaceuticals?

More information is available on their website at www.quoinpharma.com.

Tags: QNRX Viatris Investor Conferences Healthcare Quoin Pharmaceuticals rare diseases financial results conference call
Last updated: Jul 27, 2023